Abstract
This report highlights corneal epithelial changes in 3 patients receiving different antibody-drug conjugate (ADC) therapies that inhibit tubulin assembly: anetumab ravtansine for malignant pleural mesothelioma (Figure A), ado-trastuzumab emtansine for human epidermal growth factor receptor–positive ductal carcinoma of the breast (Figure B), and belantamab mafodotin for refractory myeloma (Figures C and D). The ADCs are a novel approach for treating cancer by using targeted monoclonal antibodies to direct cytotoxic payloads to malignant cells while reducing systemic toxicity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
